Trial Profile
Combination Therapy of SGLT2 Inhibitor and intensive Physical Exercises, focusing on the Prevention of Muscle Mass Reduction in Patients with Type 2 Diabetes
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 14 Dec 2021
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
- 08 Apr 2019 Status changed from active, no longer recruiting to discontinued.
- 22 Feb 2019 Status changed from recruiting to active, no longer recruiting.